NASDAQ:INCYIncyte Stock Price, Forecast & News

$86.66

+1.55 (+1.82 %)

(As of 04/8/2020 06:00 AM ET)

Add

Compare

Today's Range

$85.13

Now: $86.66▼

$87.85

50-Day Range

$63.18

MA: $74.72▼

$85.11

52-Week Range

$62.48

Now: $86.66▼

$96.79

Volume2.92 million shs

Average Volume1.98 million shs

Market Capitalization$18.79 billion

P/E Ratio42.27

Dividend YieldN/A

Beta0.8

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Incyte has received a consensus rating of Buy. The company's average rating score is 2.59, and is based on 13 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $91.16, Incyte has a potential upside of 5.2% from its current price of $86.66.
Amount of Analyst Coverage
Incyte has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Incyte has received 1,128 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Incyte has received 698 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Incyte has received 61.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote “Outperform” if you believe INCY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Incyte does not currently pay a dividend.
Dividend Growth
Incyte does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $569,184.00 in company stock.
Percentage Held by Insiders
Only 17.10% of the stock of Incyte is held by insiders.
Percentage Held by Institutions
90.66% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Incyte are expected to grow by 38.36% in the coming year, from $2.19 to $3.03 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Incyte is 42.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.02.
Price to Earnings Ratio vs. Sector
The P/E ratio of Incyte is 42.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.42.
Price to Earnings Growth Ratio
Incyte has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Incyte has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:INCY

Previous Symbol

CUSIP45337C10

CIK879169

Webhttp://www.incyte.com/

Phone302-498-6700

Debt

Debt-to-Equity Ratio0.01

Current Ratio4.83

Quick Ratio4.81

Price-To-Earnings

Trailing P/E Ratio42.27

Forward P/E Ratio39.57

P/E Growth1.11

Sales & Book Value

Annual Sales$2.16 billion

Price / Sales8.70

Cash Flow$2.76 per share

Price / Cash Flow31.41

Book Value$12.06 per share

Price / Book7.19

Profitability

EPS (Most Recent Fiscal Year)$2.23

Net Income$446.91 million

Net Margins20.70%

Return on Equity20.05%

Return on Assets15.19%

Miscellaneous

Employees1,456

Outstanding Shares216,776,000

Market Cap$18.79 billion

Next Earnings Date5/5/2020 (Estimated)

OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 20.5% and is now trading at $86.66. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Incyte?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Incyte.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.57 by $0.08. The biopharmaceutical company had revenue of $579.40 million for the quarter, compared to analysts' expectations of $558.13 million. Incyte had a net margin of 20.70% and a return on equity of 20.05%. Incyte's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.40 earnings per share. View Incyte's earnings history.

What price target have analysts set for INCY?

22 analysts have issued 1 year price targets for Incyte's stock. Their forecasts range from $74.00 to $121.00. On average, they expect Incyte's stock price to reach $91.16 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View analysts' price targets for Incyte.

Has Incyte been receiving favorable news coverage?

News headlines about INCY stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutIncyte.

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,880,000 shares, an increase of 19.0% from the February 13th total of 4,100,000 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is presently 3.0 days. Currently, 2.3% of the company's shares are sold short. View Incyte's Current Options Chain.

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Who are Incyte's key executives?

Incyte's management team includes the following people:

Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.01%) and IBM Retirement Fund (0.00%). Company insiders that own Incyte stock include Barry P Flannelly, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends for Incyte.

Which institutional investors are buying Incyte stock?

INCY stock was acquired by a variety of institutional investors in the last quarter, including IBM Retirement Fund, and State of Alaska Department of Revenue. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot, and Jean Jacques Bienaime. View insider buying and selling activity for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $86.66.

How big of a company is Incyte?

Incyte has a market capitalization of $18.79 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe. View additional information about Incyte.

What is Incyte's official website?

The official website for Incyte is http://www.incyte.com/.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

NASDAQ:INCYIncyte Stock Price, Forecast & News

Adding

Adding

Adding Incyte Co.

Beat the Market (BTM) Rank™

2.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

3.1 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment